Report Detail
Global and United States Granulomatosis with Polyangiitis Drug Market Insights, Forecast to 2026
- RnM4198965 |
- 10 September, 2020 |
- Global |
- 132 Pages |
- QYResearch |
- Pharma & Healthcare
Granulomatosis with Polyangiitis Drug market is segmented by region (country), players, by Type, and by Application. Players, stakeholders, and other participants in the global Granulomatosis with Polyangiitis Drug market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by region (country), by Type and by Application in terms of revenue and forecast for the period 2015-2026.
Segment by Type, the Granulomatosis with Polyangiitis Drug market is segmented into
Benralizumab
Avacopan
Rituximab Biosimilar
Others
Segment by Application, the Granulomatosis with Polyangiitis Drug market is segmented into
Hospital
Clinic
Others
Regional and Country-level Analysis
The Granulomatosis with Polyangiitis Drug market is analysed and market size information is provided by regions (countries).
The key regions covered in the Granulomatosis with Polyangiitis Drug market report are North America, Europe, Asia Pacific, Latin America, Middle East and Africa. It also covers key regions (countries), viz, U.S., Canada, Germany, France, U.K., Italy, Russia, China, Japan, South Korea, India, Australia, Taiwan, Indonesia, Thailand, Malaysia, Philippines, Vietnam, Mexico, Brazil, Turkey, Saudi Arabia, U.A.E, etc.
The report includes country-wise and region-wise market size for the period 2015-2026. It also includes market size and forecast by Type, and by Application segment in terms of sales and revenue for the period 2015-2026.
Competitive Landscape and Granulomatosis with Polyangiitis Drug Market Share Analysis
Granulomatosis with Polyangiitis Drug market competitive landscape provides details and data information by players. The report offers comprehensive analysis and accurate statistics on revenue by the player for the period 2015-2020. It also offers detailed analysis supported by reliable statistics on revenue (global and regional level) by players for the period 2015-2020. Details included are company description, major business, company total revenue and the sales, revenue generated in Granulomatosis with Polyangiitis Drug business, the date to enter into the Granulomatosis with Polyangiitis Drug market, Granulomatosis with Polyangiitis Drug product introduction, recent developments, etc.
The major vendors covered:
Bionovis SA
Bristol-Myers Squibb Company
ChemoCentryx Inc
Coherus BioSciences Inc
Genor BioPharma Co Ltd
GlaxoSmithKline Plc
Iltoo Pharma
Panacea Biotec Ltd
Sandoz International GmbH
The International Biotechnology Center (IBC) Generium
1 Study Coverage
- 1.1 Granulomatosis with Polyangiitis Drug Product Introduction
- 1.2 Market Segments
- 1.3 Key Granulomatosis with Polyangiitis Drug Manufacturers Covered: Ranking by Revenue
- 1.4 Market by Type
- 1.4.1 Global Granulomatosis with Polyangiitis Drug Market Size Growth Rate by Type
- 1.4.2 Benralizumab
- 1.4.3 Avacopan
- 1.4.4 Rituximab Biosimilar
- 1.4.5 Others
- 1.5 Market by Application
- 1.5.1 Global Granulomatosis with Polyangiitis Drug Market Size Growth Rate by Application
- 1.5.2 Hospital
- 1.5.3 Clinic
- 1.5.4 Others
- 1.6 Study Objectives
- 1.7 Years Considered
2 Executive Summary
- 2.1 Global Granulomatosis with Polyangiitis Drug Market Size, Estimates and Forecasts
- 2.1.1 Global Granulomatosis with Polyangiitis Drug Revenue 2015-2026
- 2.1.2 Global Granulomatosis with Polyangiitis Drug Sales 2015-2026
- 2.2 Global Granulomatosis with Polyangiitis Drug, Market Size by Producing Regions: 2015 VS 2020 VS 2026
- 2.3 Granulomatosis with Polyangiitis Drug Historical Market Size by Region (2015-2020)
- 2.3.1 Global Granulomatosis with Polyangiitis Drug Retrospective Market Scenario in Sales by Region: 2015-2020
- 2.3.2 Global Granulomatosis with Polyangiitis Drug Retrospective Market Scenario in Revenue by Region: 2015-2020
- 2.4 Granulomatosis with Polyangiitis Drug Market Estimates and Projections by Region (2021-2026)
- 2.4.1 Global Granulomatosis with Polyangiitis Drug Sales Forecast by Region (2021-2026)
- 2.4.2 Global Granulomatosis with Polyangiitis Drug Revenue Forecast by Region (2021-2026)
3 Global Granulomatosis with Polyangiitis Drug Competitor Landscape by Players
- 3.1 Global Top Granulomatosis with Polyangiitis Drug Sales by Manufacturers
- 3.1.1 Global Granulomatosis with Polyangiitis Drug Sales by Manufacturers (2015-2020)
- 3.1.2 Global Granulomatosis with Polyangiitis Drug Sales Market Share by Manufacturers (2015-2020)
- 3.2 Global Granulomatosis with Polyangiitis Drug Manufacturers by Revenue
- 3.2.1 Global Granulomatosis with Polyangiitis Drug Revenue by Manufacturers (2015-2020)
- 3.2.2 Global Granulomatosis with Polyangiitis Drug Revenue Share by Manufacturers (2015-2020)
- 3.2.3 Global Granulomatosis with Polyangiitis Drug Market Concentration Ratio (CR5 and HHI) (2015-2020)
- 3.2.4 Global Top 10 and Top 5 Companies by Granulomatosis with Polyangiitis Drug Revenue in 2019
- 3.2.5 Global Granulomatosis with Polyangiitis Drug Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
- 3.3 Global Granulomatosis with Polyangiitis Drug Price by Manufacturers
- 3.4 Global Granulomatosis with Polyangiitis Drug Manufacturing Base Distribution, Product Types
- 3.4.1 Granulomatosis with Polyangiitis Drug Manufacturers Manufacturing Base Distribution, Headquarters
- 3.4.2 Manufacturers Granulomatosis with Polyangiitis Drug Product Type
- 3.4.3 Date of International Manufacturers Enter into Granulomatosis with Polyangiitis Drug Market
- 3.5 Manufacturers Mergers & Acquisitions, Expansion Plans
4 Market Size by Type (2015-2026)
- 4.1 Global Granulomatosis with Polyangiitis Drug Market Size by Type (2015-2020)
- 4.1.1 Global Granulomatosis with Polyangiitis Drug Sales by Type (2015-2020)
- 4.1.2 Global Granulomatosis with Polyangiitis Drug Revenue by Type (2015-2020)
- 4.1.3 Granulomatosis with Polyangiitis Drug Average Selling Price (ASP) by Type (2015-2026)
- 4.2 Global Granulomatosis with Polyangiitis Drug Market Size Forecast by Type (2021-2026)
- 4.2.1 Global Granulomatosis with Polyangiitis Drug Sales Forecast by Type (2021-2026)
- 4.2.2 Global Granulomatosis with Polyangiitis Drug Revenue Forecast by Type (2021-2026)
- 4.2.3 Granulomatosis with Polyangiitis Drug Average Selling Price (ASP) Forecast by Type (2021-2026)
- 4.3 Global Granulomatosis with Polyangiitis Drug Market Share by Price Tier (2015-2020): Low-End, Mid-Range and High-End
5 Market Size by Application (2015-2026)
- 5.1 Global Granulomatosis with Polyangiitis Drug Market Size by Application (2015-2020)
- 5.1.1 Global Granulomatosis with Polyangiitis Drug Sales by Application (2015-2020)
- 5.1.2 Global Granulomatosis with Polyangiitis Drug Revenue by Application (2015-2020)
- 5.1.3 Granulomatosis with Polyangiitis Drug Price by Application (2015-2020)
- 5.2 Granulomatosis with Polyangiitis Drug Market Size Forecast by Application (2021-2026)
- 5.2.1 Global Granulomatosis with Polyangiitis Drug Sales Forecast by Application (2021-2026)
- 5.2.2 Global Granulomatosis with Polyangiitis Drug Revenue Forecast by Application (2021-2026)
- 5.2.3 Global Granulomatosis with Polyangiitis Drug Price Forecast by Application (2021-2026)
6 United States by Players, Type and Application
- 6.1 United States Granulomatosis with Polyangiitis Drug Market Size YoY Growth 2015-2026
- 6.1.1 United States Granulomatosis with Polyangiitis Drug Sales YoY Growth 2015-2026
- 6.1.2 United States Granulomatosis with Polyangiitis Drug Revenue YoY Growth 2015-2026
- 6.1.3 United States Granulomatosis with Polyangiitis Drug Market Share in Global Market 2015-2026
- 6.2 United States Granulomatosis with Polyangiitis Drug Market Size by Players (International and Local Players)
- 6.2.1 United States Top Granulomatosis with Polyangiitis Drug Players by Sales (2015-2020)
- 6.2.2 United States Top Granulomatosis with Polyangiitis Drug Players by Revenue (2015-2020)
- 6.3 United States Granulomatosis with Polyangiitis Drug Historic Market Review by Type (2015-2020)
- 6.3.1 United States Granulomatosis with Polyangiitis Drug Sales Market Share by Type (2015-2020)
- 6.3.2 United States Granulomatosis with Polyangiitis Drug Revenue Market Share by Type (2015-2020)
- 6.3.3 United States Granulomatosis with Polyangiitis Drug Price by Type (2015-2020)
- 6.4 United States Granulomatosis with Polyangiitis Drug Market Estimates and Forecasts by Type (2021-2026)
- 6.4.1 United States Granulomatosis with Polyangiitis Drug Sales Forecast by Type (2021-2026)
- 6.4.2 United States Granulomatosis with Polyangiitis Drug Revenue Forecast by Type (2021-2026)
- 6.4.3 United States Granulomatosis with Polyangiitis Drug Price Forecast by Type (2021-2026)
- 6.5 United States Granulomatosis with Polyangiitis Drug Historic Market Review by Application (2015-2020)
- 6.5.1 United States Granulomatosis with Polyangiitis Drug Sales Market Share by Application (2015-2020)
- 6.5.2 United States Granulomatosis with Polyangiitis Drug Revenue Market Share by Application (2015-2020)
- 6.5.3 United States Granulomatosis with Polyangiitis Drug Price by Application (2015-2020)
- 6.6 United States Granulomatosis with Polyangiitis Drug Market Estimates and Forecasts by Application (2021-2026)
- 6.6.1 United States Granulomatosis with Polyangiitis Drug Sales Forecast by Application (2021-2026)
- 6.6.2 United States Granulomatosis with Polyangiitis Drug Revenue Forecast by Application (2021-2026)
- 6.6.3 United States Granulomatosis with Polyangiitis Drug Price Forecast by Application (2021-2026)
7 North America
- 7.1 North America Granulomatosis with Polyangiitis Drug Market Size YoY Growth 2015-2026
- 7.2 North America Granulomatosis with Polyangiitis Drug Market Facts & Figures by Country
- 7.2.1 North America Granulomatosis with Polyangiitis Drug Sales by Country (2015-2020)
- 7.2.2 North America Granulomatosis with Polyangiitis Drug Revenue by Country (2015-2020)
- 7.2.3 U.S.
- 7.2.4 Canada
8 Europe
- 8.1 Europe Granulomatosis with Polyangiitis Drug Market Size YoY Growth 2015-2026
- 8.2 Europe Granulomatosis with Polyangiitis Drug Market Facts & Figures by Country
- 8.2.1 Europe Granulomatosis with Polyangiitis Drug Sales by Country
- 8.2.2 Europe Granulomatosis with Polyangiitis Drug Revenue by Country
- 8.2.3 Germany
- 8.2.4 France
- 8.2.5 U.K.
- 8.2.6 Italy
- 8.2.7 Russia
9 Asia Pacific
- 9.1 Asia Pacific Granulomatosis with Polyangiitis Drug Market Size YoY Growth 2015-2026
- 9.2 Asia Pacific Granulomatosis with Polyangiitis Drug Market Facts & Figures by Country
- 9.2.1 Asia Pacific Granulomatosis with Polyangiitis Drug Sales by Region (2015-2020)
- 9.2.2 Asia Pacific Granulomatosis with Polyangiitis Drug Revenue by Region
- 9.2.3 China
- 9.2.4 Japan
- 9.2.5 South Korea
- 9.2.6 India
- 9.2.7 Australia
- 9.2.8 Taiwan
- 9.2.9 Indonesia
- 9.2.10 Thailand
- 9.2.11 Malaysia
- 9.2.12 Philippines
- 9.2.13 Vietnam
10 Latin America
- 10.1 Latin America Granulomatosis with Polyangiitis Drug Market Size YoY Growth 2015-2026
- 10.2 Latin America Granulomatosis with Polyangiitis Drug Market Facts & Figures by Country
- 10.2.1 Latin America Granulomatosis with Polyangiitis Drug Sales by Country
- 10.2.2 Latin America Granulomatosis with Polyangiitis Drug Revenue by Country
- 10.2.3 Mexico
- 10.2.4 Brazil
- 10.2.5 Argentina
11 Middle East and Africa
- 11.1 Middle East and Africa Granulomatosis with Polyangiitis Drug Market Size YoY Growth 2015-2026
- 11.2 Middle East and Africa Granulomatosis with Polyangiitis Drug Market Facts & Figures by Country
- 11.2.1 Middle East and Africa Granulomatosis with Polyangiitis Drug Sales by Country
- 11.2.2 Middle East and Africa Granulomatosis with Polyangiitis Drug Revenue by Country
- 11.2.3 Turkey
- 11.2.4 Saudi Arabia
- 11.2.5 U.A.E
12 Company Profiles
- 12.1 Bionovis SA
- 12.1.1 Bionovis SA Corporation Information
- 12.1.2 Bionovis SA Description and Business Overview
- 12.1.3 Bionovis SA Sales, Revenue and Gross Margin (2015-2020)
- 12.1.4 Bionovis SA Granulomatosis with Polyangiitis Drug Products Offered
- 12.1.5 Bionovis SA Recent Development
- 12.2 Bristol-Myers Squibb Company
- 12.2.1 Bristol-Myers Squibb Company Corporation Information
- 12.2.2 Bristol-Myers Squibb Company Description and Business Overview
- 12.2.3 Bristol-Myers Squibb Company Sales, Revenue and Gross Margin (2015-2020)
- 12.2.4 Bristol-Myers Squibb Company Granulomatosis with Polyangiitis Drug Products Offered
- 12.2.5 Bristol-Myers Squibb Company Recent Development
- 12.3 ChemoCentryx Inc
- 12.3.1 ChemoCentryx Inc Corporation Information
- 12.3.2 ChemoCentryx Inc Description and Business Overview
- 12.3.3 ChemoCentryx Inc Sales, Revenue and Gross Margin (2015-2020)
- 12.3.4 ChemoCentryx Inc Granulomatosis with Polyangiitis Drug Products Offered
- 12.3.5 ChemoCentryx Inc Recent Development
- 12.4 Coherus BioSciences Inc
- 12.4.1 Coherus BioSciences Inc Corporation Information
- 12.4.2 Coherus BioSciences Inc Description and Business Overview
- 12.4.3 Coherus BioSciences Inc Sales, Revenue and Gross Margin (2015-2020)
- 12.4.4 Coherus BioSciences Inc Granulomatosis with Polyangiitis Drug Products Offered
- 12.4.5 Coherus BioSciences Inc Recent Development
- 12.5 Genor BioPharma Co Ltd
- 12.5.1 Genor BioPharma Co Ltd Corporation Information
- 12.5.2 Genor BioPharma Co Ltd Description and Business Overview
- 12.5.3 Genor BioPharma Co Ltd Sales, Revenue and Gross Margin (2015-2020)
- 12.5.4 Genor BioPharma Co Ltd Granulomatosis with Polyangiitis Drug Products Offered
- 12.5.5 Genor BioPharma Co Ltd Recent Development
- 12.6 GlaxoSmithKline Plc
- 12.6.1 GlaxoSmithKline Plc Corporation Information
- 12.6.2 GlaxoSmithKline Plc Description and Business Overview
- 12.6.3 GlaxoSmithKline Plc Sales, Revenue and Gross Margin (2015-2020)
- 12.6.4 GlaxoSmithKline Plc Granulomatosis with Polyangiitis Drug Products Offered
- 12.6.5 GlaxoSmithKline Plc Recent Development
- 12.7 Iltoo Pharma
- 12.7.1 Iltoo Pharma Corporation Information
- 12.7.2 Iltoo Pharma Description and Business Overview
- 12.7.3 Iltoo Pharma Sales, Revenue and Gross Margin (2015-2020)
- 12.7.4 Iltoo Pharma Granulomatosis with Polyangiitis Drug Products Offered
- 12.7.5 Iltoo Pharma Recent Development
- 12.8 Panacea Biotec Ltd
- 12.8.1 Panacea Biotec Ltd Corporation Information
- 12.8.2 Panacea Biotec Ltd Description and Business Overview
- 12.8.3 Panacea Biotec Ltd Sales, Revenue and Gross Margin (2015-2020)
- 12.8.4 Panacea Biotec Ltd Granulomatosis with Polyangiitis Drug Products Offered
- 12.8.5 Panacea Biotec Ltd Recent Development
- 12.9 Sandoz International GmbH
- 12.9.1 Sandoz International GmbH Corporation Information
- 12.9.2 Sandoz International GmbH Description and Business Overview
- 12.9.3 Sandoz International GmbH Sales, Revenue and Gross Margin (2015-2020)
- 12.9.4 Sandoz International GmbH Granulomatosis with Polyangiitis Drug Products Offered
- 12.9.5 Sandoz International GmbH Recent Development
- 12.10 The International Biotechnology Center (IBC) Generium
- 12.10.1 The International Biotechnology Center (IBC) Generium Corporation Information
- 12.10.2 The International Biotechnology Center (IBC) Generium Description and Business Overview
- 12.10.3 The International Biotechnology Center (IBC) Generium Sales, Revenue and Gross Margin (2015-2020)
- 12.10.4 The International Biotechnology Center (IBC) Generium Granulomatosis with Polyangiitis Drug Products Offered
- 12.10.5 The International Biotechnology Center (IBC) Generium Recent Development
- 12.11 Bionovis SA
- 12.11.1 Bionovis SA Corporation Information
- 12.11.2 Bionovis SA Description and Business Overview
- 12.11.3 Bionovis SA Sales, Revenue and Gross Margin (2015-2020)
- 12.11.4 Bionovis SA Granulomatosis with Polyangiitis Drug Products Offered
- 12.11.5 Bionovis SA Recent Development
13 Market Opportunities, Challenges, Risks and Influences Factors Analysis
- 13.1 Market Opportunities and Drivers
- 13.2 Market Challenges
- 13.3 Market Risks/Restraints
- 13.4 Porter’s Five Forces Analysis
- 13.5 Primary Interviews with Key Granulomatosis with Polyangiitis Drug Players (Opinion Leaders)
14 Value Chain and Sales Channels Analysis
- 14.1 Value Chain Analysis
- 14.2 Granulomatosis with Polyangiitis Drug Customers
- 14.3 Sales Channels Analysis
- 14.3.1 Sales Channels
- 14.3.2 Distributors
15 Research Findings and Conclusion
16 Appendix
- 16.1 Research Methodology
- 16.1.1 Methodology/Research Approach
- 16.1.2 Data Source
- 16.2 Author Details
Summary:
Get latest Market Research Reports on Granulomatosis with Polyangiitis Drug. Industry analysis & Market Report on Granulomatosis with Polyangiitis Drug is a syndicated market report, published as Global and United States Granulomatosis with Polyangiitis Drug Market Insights, Forecast to 2026. It is complete Research Study and Industry Analysis of Granulomatosis with Polyangiitis Drug market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.
REPORT YOU MIGHT BE INTERESTED
Related Reports
Reason to Buy
Reports and Markets
Contact Us
+1-352-353-0818 (US)Newsletter
KEEP UP TO DATE ON ALL THE LATEST REPORTS
